Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Cancers|February 11, 2023
Significant Tumor Regression after Neoadjuvant Chemotherapy in Gastric Cancer, but Poor Survival of the Patient? Role of MHC Class I AlterationsTheresa Hiltner, Noémi Szörenyi, Meike Kohlruss, et al.
Journal of Surgical Oncology|August 26, 2015
Surgery of gastric cancer and esophageal cancer: Does age matter?Henrik Nienhueser, Romy Kunzmann, Leila Sisic, et al.
Journal of Cancer Research and Clinical Oncology|October 11, 2023
Low microsatellite instability: A distinct instability type in gastric cancer?Meike Kohlruss, Shounak Chakraborty, Alexander Hapfelmeier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trialKatja Ott, Ulrich Fink, Karen Becker, et al.
Cancers|July 8, 2020
Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric CancerBianca Grosser, Meike Kohlruss, Julia Slotta-Huspenina, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 8, 2018
Prognostic differences in 8th edition TNM staging of esophagogastric adenocarcinoma after neoadjuvant treatmentLeila Sisic, Susanne Blank, Henrik Nienhüser, et al.
Plos One|June 14, 2018
A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomasOlivia Adams, Félice A Janser, Bastian Dislich, et al.
Plos One|October 31, 2019
Correction: A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomasOlivia Adams, Félice A Janser, Bastian Dislich, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2007
Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysisKen Herrmann, Katja Ott, Andreas K Buck, et al.
The Journal of Pathology. Clinical Research|June 18, 2022
Post-neoadjuvant assessment of tumour budding according to ITBCC subgroups delivers stage- and regression-grade independent prognostic information in intestinal-type gastric adenocarcinomaMoritz Jesinghaus, Anna-Lina Herz, Meike Kohlruss, et al.
Pageof 12